Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2018

Primary Completion Date

December 11, 2023

Study Completion Date

December 11, 2023

Conditions
Pancreatic CancerPancreatic Ductal AdenocarcinomaPancreatic AdenocarcinomaPancreas MetastasesAdenocarcinoma
Interventions
DRUG

Paricalcitol (Zemplar)

combination therapy

Trial Locations (1)

85258

HonorHealth Research Institute, Scottsdale

All Listed Sponsors
collaborator

Barts Cancer Institute

OTHER

collaborator

Abramson Cancer Center at Penn Medicine

OTHER

collaborator

Salk Institute for Biological Studies

OTHER

collaborator

Mayo Clinic

OTHER

collaborator

Princeton University

OTHER

collaborator

Imaging Endpoints

UNKNOWN

collaborator

Translational Genomics Research Institute

OTHER

collaborator

Stand Up To Cancer

OTHER

collaborator

Cancer Research UK

OTHER

collaborator

Lustgarten Foundation

OTHER

collaborator

University of California, San Diego

OTHER

lead

HonorHealth Research Institute

OTHER